PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
1.95%
Revenue growth similar to AVGO's 1.82%. Walter Schloss would see if both companies share industry tailwinds.
1.45%
Gross profit growth similar to AVGO's 1.48%. Walter Schloss would assume both firms track common industry trends.
-0.33%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-0.33%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
0.90%
Net income growth under 50% of AVGO's 13.45%. Michael Burry would suspect the firm is falling well behind a key competitor.
1.79%
EPS growth under 50% of AVGO's 12.24%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
1.82%
Diluted EPS growth under 50% of AVGO's 12.50%. Michael Burry would worry about an eroding competitive position or excessive dilution.
-0.94%
Share reduction while AVGO is at 1.24%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-1.17%
Reduced diluted shares while AVGO is at 0.80%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-1.03%
Dividend reduction while AVGO stands at 16.21%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
22.29%
OCF growth under 50% of AVGO's 274.63%. Michael Burry might suspect questionable revenue recognition or rising costs.
10.25%
FCF growth under 50% of AVGO's 562.86%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
163.00%
10Y revenue/share CAGR above 1.5x AVGO's 50.51%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
25.66%
5Y revenue/share CAGR at 50-75% of AVGO's 50.51%. Martin Whitman would worry about a lagging mid-term growth trajectory.
17.83%
3Y revenue/share CAGR under 50% of AVGO's 50.51%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
66.82%
10Y OCF/share CAGR under 50% of AVGO's 232.18%. Michael Burry would worry about a persistent underperformance in cash creation.
32.66%
Below 50% of AVGO's 232.18%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
38.83%
3Y OCF/share CAGR under 50% of AVGO's 232.18%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
628.47%
Net income/share CAGR 1.25-1.5x AVGO's 480.38%. Bruce Berkowitz might see more effective use of capital or consistently better margins over time.
-62.18%
Negative 5Y net income/share CAGR while AVGO is 480.38%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
30.50%
Below 50% of AVGO's 480.38%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
33.35%
Below 50% of AVGO's 106.38%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
14.54%
Below 50% of AVGO's 106.38%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
24.70%
Below 50% of AVGO's 106.38%. Michael Burry suspects a serious short-term disadvantage in building book value.
528.07%
Dividend/share CAGR of 528.07% while AVGO is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
328.75%
Dividend/share CAGR of 328.75% while AVGO is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
29.76%
3Y dividend/share CAGR of 29.76% while AVGO is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
6.63%
Our AR growth while AVGO is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
5.01%
We show growth while AVGO is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
28.46%
Asset growth above 1.5x AVGO's 10.45%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
4.09%
50-75% of AVGO's 7.61%. Martin Whitman suspects weaker earnings or capital allocation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
0.47%
R&D dropping or stable vs. AVGO's 4.11%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
3.79%
SG&A declining or stable vs. AVGO's 10.00%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.